In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a LAMIVUDINE, NEVIRAPINE, AND STAVUDINE Drug Master File in Korea (LAMIVUDINE, NEVIRAPINE, AND STAVUDINE KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of LAMIVUDINE, NEVIRAPINE, AND STAVUDINE. The MFDS reviews the LAMIVUDINE, NEVIRAPINE, AND STAVUDINE KDMF as part of the drug registration process and uses the information provided in the LAMIVUDINE, NEVIRAPINE, AND STAVUDINE KDMF to evaluate the safety and efficacy of the drug.
After submitting a LAMIVUDINE, NEVIRAPINE, AND STAVUDINE KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their LAMIVUDINE, NEVIRAPINE, AND STAVUDINE API can apply through the Korea Drug Master File (KDMF).
click here to find a list of LAMIVUDINE, NEVIRAPINE, AND STAVUDINE suppliers with KDMF on PharmaCompass.